Tomorrow, we're joining global leaders, policymakers, scientists, and health experts as a featured speaker at the “Healthy #IndoorAir: A Global Call to Action” event, an official side event of #UNGA80. Watch it live at 3 p.m. EDT: bit.ly/4nfJbj5

We made water safe with filtration & disinfection. Now we can do the same for air with ventilation, filtration, and germicidal light, as illustrated in our latest @worksinprogress.bsky.social piece. (1/10)

New Nature Reviews Immunology paper: "Targets of protective immunity & opportunities in hepatitis C virus vaccine development" explores the current landscape, including subunit, virus-like particle, viral vector, DNA & RNA vaccines, and controlled human infection models. Read at bit.ly/4md5EvH.

We've launched the first-ever Cooperative Participant Organization (CPO) for clinical trials, connecting academic researchers with motivated healthy volunteers for crucial studies. Community trust + expertise from former participants = game-changing support for researchers. bit.ly/4mlY3ey

Proud to have signed on to this act. Looking forward to seeing progress on indoor air quality!

We are hiring! If you are passionate about reducing the burden of infectious diseases worldwide, 1Day is seeking contractors to work on our African Medicines Agency engagement and using AI in the FDA projects. Apply today at www.1daysooner.org/jobs/.

🚨 We're hiring a People Operations Lead! 🚨 🧠Own HR, onboarding, benefits, & culture. 🌎Remote-first international nonprofit. 🤝 High autonomy + direct access to leadership. 💼HR pros with 2+ yrs. of experience. Apply by July 18. www.1daysooner.org/jobs/

Last chance to register for tomorrow's webinar! bit.ly/4le0yzu

Join us & @scientistsorg.bsky.social on 6/24 for a webinar on opportunities to integrate AI in the HHS. Experts will discuss implementation case studies, talent pathways like a proposed AI Corps, research opportunities, and public-private collaboration. Register today! bit.ly/4le0yzu

Join us in D.C. for a happy hour on fair compensation in clinical trials! Meet the authors of the new American Journal of Bioethics open letter on ethical pay for participants & connect with changemakers over drinks. Register today: bit.ly/4e5yHz2

ICYMI: 64 experts have published an open letter in The American Journal of Bioethics, calling for a reexamination of entrenched attitudes toward payment for clinical research participation. bit.ly/4kWd06R

Check out our latest news in our May newsletter: mailchi.mp/1daysooner.o....

As the FDA faces significant staffing reductions, there could be ripple effects for US companies & leadership in the biomedical space, as well as for other countries that depend on FDA's leadership to enable access to key health tools. @ghtcoalition.org bit.ly/3T0S1U8

Why are we so afraid to fairly compensate research participants? 64 experts challenge the idea that payment = undue influence. Read our open letter in The American Journal of Bioethics highlighting the pitfalls of excessive concern over payment to research participants. bit.ly/43vpdbo

On #ClinicalTrialsDay, we thank the volunteers who have stepped forward to participate in human challenge studies. Your selflessness and commitment to advancing science have played a vital role in improving public health. Sign up to learn more on how to participate: www.1daysooner.org/volunteer/.

Bipartisan momentum for U.S. biotech: The National Biotechnology Initiative Act of 2025 would create a White House-led office to coordinate federal biotech strategy across security, economy & innovation. www.biotech.senate.gov/press-releas...

Policymakers from 11 African countries met for #COPEMA's first regional summit to fight malaria. We are proud to see our cost analysis shared by another presenter and to have 1Day Africa's Zach Kauko share our work! Read our cost analysis here: www.1daysooner.org/cost-effecti....

On #WorldMalariaDay, we’re reminded that access & vaccine costs can mean life or death. 🦟 Malaria caused 249M cases & 608K deaths in 2022 alone. It’s time to embrace this year's theme: "reinvest, reimagine, reignite." 1Day Africa’s Dir spoke with The Economist on bridging this gap. bit.ly/4cPGeBs

📣April newsletter drop! Check out our latest and greatest: bit.ly/3Yeo86a.

New study in Vaccine says COVID human challenge trials (HCTs) aren’t “too risky”—they may be low or even minimal risk for eligible volunteers. Time to reassess how we evaluate HCTs in pandemics. bit.ly/3YeLngi

ICYMI, our latest webinar, "Volunteering in Controlled Human Infection Model Studies," features a panel of experts answering all your burning questions about participating in a human challenge trial. Watch at bit.ly/4igtDrT.

We are hiring a Volunteer Coordinator for our Cooperative Participant Organization. We are seeking a person ✔️ Passionate about advocating for clinical trial participants ✔️ Skilled in executing targeted outreach strategies ✔️ Ideally located in Europe or the United Kingdom Apply today: bit.ly/4cAwBGp

Our full response to the U.S. government's RFI on AI and public health is now public! We dig into how AI can help us speed up biomedical research and be a tool for good. Read it here: bit.ly/42cU0dG

💥 A blinded #StrepA human challenge PK/PD RCT 💥 All-star collaboration between @thekidsau.bsky.social & #MCRI & #UWA. @hicvac.bsky.social @1daysooner.bsky.social Thanks @onisillos.bsky.social @lancetmicrobe.bsky.social for support of human challenge research! www.thelancet.com/journals/lan...

New in Global Forum: "Unearthing the FDA’s Treasure Trove: Using AI to Revolutionize Drug Development" explores how AI can use clinical trial data to unlock smarter, faster, and more efficient drug development. A must-read for regulatory affairs, data science, or drug R&D. bit.ly/3Yui1uk

Want to be part of medical breakthroughs? Join our webinar this Thursday to learn about volunteering in human challenge trials and connect with medical experts and fellow volunteers in a live Q&A. bit.ly/4c67LON hashtag#CHIMs hashtag#MedicalResearch hashtag#Volunteer

We're 1 week away from our "Volunteering for Controlled Human Infection Model Studies" webinar. Register today to learn about this fast-growing medical research and how to get involved: bit.ly/4c67LON. Even if you can't attend, a recording will be sent to all registrants.

Register today for our Apr. 10 "Volunteering for Controlled Human Infection Model Studies." Panelists will share their personal experiences while detailing the current state of CHIMs as a growing research field. Can't attend? The recording and Q&A will be sent to all registrants: bit.ly/4c67LON.

Our latest memo, "Building on the Success of Operation Warp Speed (OWS)," details how OWS principles can be applied beyond emergencies, particularly in biomedical innovation. Check out our OWS methodology and potential Warp 2 targets: bit.ly/4iAzQjH.

Join 1Day Sooner and other stakeholders on April 3 in Washington, DC, for a Prescription Drug User Fee Act (PDUFA) VIII networking happy hour. Make connections and start planning ahead of the PDUFA VIII reauthorization public comment period. Register here: bit.ly/4igY8Ps.

New paper: Biosecurity Considerations of Controlled Human Infection Model Studies examines onward transmission of pathogens, information hazards, and challenge agent manufacturing risks & proposes risk mitigation strategies without compromising biosecurity & the role of these studies. bit.ly/4kF6CkK

Promising news: Japan is assessing whether human challenge trials should be introduced for vaccine and drug development to prepare for infectious disease outbreaks. www.asahi.com/ajw/articles...

Results from the world's first perinatal controlled human infection model (CHIM) demonstrate that CHIMs are feasible in pregnancy. Full details of the study investigating microbiome transmission in mother-infant pairs published in The Lancet Microbe: bit.ly/43iK3w1

After 80 years, researchers still struggle to make highly effective influenza vaccines. Advances in disease surveillance and next-generation adjuvants bring “universal” flu vaccines within reach, conferring lifelong immunity against any strain of flu. bit.ly/41ypef5

We proposed 10 health policy proposals for Trump's health team.

Adverse event reporting across controlled human infection studies is inconsistent, making data aggregation and reuse difficult. Our new paper evaluates the use of ClinicalTrials.gov for CHIS data reporting and compares itwith the same data in corresponding published articles. bit.ly/41boTyz

1Day's Josh Morrison talks about challenges to vaccine development, lessons learned from Operation Warp Speed and other industries, and how to get ready for the next public health challenge on Rubicon Founders' latest episode of their #AtTheCrossing podcast: bit.ly/3WQtow6

"Would You Get Sick in the Name of Science?" We spoke with @nytimes.com on 1Day's inception during the COVID pandemic and our mission to advocate for challenge trial volunteers. Read more to learn about the researchers and trial volunteers advancing health. bit.ly/4jAcAD0

Despite the potential to prevent up to 800,000 child deaths from malaria by 2030, Gavi would need to triple its $1.4B malaria vaccine budget to buy and deploy all available doses. Vox covers the latest report from the Center for Global Development & 1Day Sooner: bit.ly/3CpH75W

Participants in controlled human infection studies want (1) increased compensation, (2) enhanced comfort during the study period, (3) less disruption to their daily lives, and (4) a broad social benefit arising from their participation in medical research. Here's the full report: bit.ly/42nLoRN.

The pharma industry frequently cites review delays and limited availability of FDA interactions as a key bottleneck in drug approval processes. "Improving Regulator Capacity through AI" lays out recommendations for integrating AI to enhance existing FDA reviewers: adobe.ly/42qmDES

We are deeply saddened by the passing of Paul Mango. He was not only a kind and thoughtful person but also a visionary leader who generously shared his time and expertise to support our mission. We are forever grateful for his guidance and belief in our work. Our hearts go out to his family.

Unfair compensation for participants is one of the reasons recruitment is a problem in U.S. clinical trials. We must: 1. Update regulations to stop institutional review boards from limiting compensation. 2. Exempt trial income from taxes. Here's how: adobe.ly/4jl8Pl2

American healthcare can be better delivered through the establishment of an AI Corps throughout the Department of Health and Human Services's 10 agencies, according to our recent report. Our action plan uses the FDA as a case study for the @scientistsorg.bsky.social Day One project: bit.ly/3WjcAgF

Challenge trials can de-risk product development by providing earlier in-human data for pathogen vaccines or treatments. But U.S. use is limited by unclear regulatory and approval barriers. Our latest @ifp.bsky.social Clinical Trials Abundance policy paper lays out how to fix it. adobe.ly/3WdzTss

ICYMI: 1Day founder & president Josh Morrison was a recent guest on the Complex Systems podcast talking about Operation Warp Speed, lessons learned and as-yet unlearned about the pandemic, and a peek at near-future technology against infectious disease. bit.ly/3C5CWMg

Missed what we've been up to? Read our final newsletter of 2024, covering our latest policy recommendations and whitepapers, takeaways from our annual Operation Warp Speed 2.0 conference, and more: bit.ly/40niZKu.

This year I traveled to Nigeria, DRC, Malawi, and Mozambique, and bothered a lot of people about this, so am happy to finally share this piece, joint with Ryan Duncombe and Karam Elabd from @1daysooner.bsky.social Full paper: www.cgdev.org/publication/... Blog summary: cgdev.org/blog/malaria...

The world is aging. Today, some two thirds of the global population is dying from an age-related condition. By 2029, the U.S. will spend roughly $3 trillion dollars yearly – half the federal budget – on adults aged 65 and older. FDA, NIH, ARPA-H, and BARDA can do something🧵

We just wrapped our third annual Operation Warp Speed 2.0 conference on “Applying Pull Funding & Regulatory Capacity to Advance New Biotechnologies & Prevent Pandemics." Read all about the event: bit.ly/4fabVVC. Thank you to all our speakers, organizers, and staff that made the event such a success!